The BK channel protein is a multimeric structure (homotetramer) composed of four identical pore-forming α subunits (BKα), encoded by a single gene (Slo1, KCNMA1). Each BKα has seven trans-membrane segments (S0-S6) and a large intracellular C-terminus region. The BKα protein shows three main structural domains, each with a distinct function. The voltage-sensing domain (VSD) is located within the S1-S4 transmembrane segments, able to sense membrane potential. The S5-S6 segments form the pore gate domain (PGD) including the activation gate, which controls K+ flux through the channel. The S6 segment serves as the major structural determinant for the channel gate. The primary voltage sensor is located on the S4 helix, which contains many positively charged residues, but only one of these participates in voltage sensing. The membrane-spanning domains VSD and PGD, interact through the S4-S5 linker and S6, and the hydrophobic segment (S0) leads to an extracellular NH2 terminus. The third domain is the cytosolic domain (CTD), which enables the channel to respond to changes in [Ca2+]i and other stimuli. The intracellular Cterminus has two tandem RCK (regulator of K+ conductance) domains, RCK1 and RCK2, folded tightly against each other. Channel sensitivity to Ca2+ is determined by a gating ring of eight RCK domains from the four assembled α subunits; this gating ring is subjected to an expansion during channel gating. RCK2 domains have an aspartate-rich region that forms the 'Ca2+ bowl', showing a high Ca2+ affinity. A lowaffinity Ca2+ recognition site has also been identified within the RCK1 domain, where another high-affinity Ca2+site is also present. RCK1 also mediates the channel's sensitivity to Mg2+, Zn2+and Cd2+. The four β-subunits (β1-4) are encoded by a specific gene KCNMB1-4 (human) or kcnmb 1-4 (mouse). These BK channel subunits have two transmembrane domains (TM1 and TM2) connected by a large loop on the extracellular side. β-subunits also show an intracellular N-terminus and C-terminus. Each β-subunit is located between two adjacent α-subunits. γ subunits contain a single transmembrane domain, an N-terminal extracellular LRRD (leucine-rich repeat domain), and a short C-terminal tail. 389x245mm (72 x 72 DPI) 
Highlights Box
• BK channels control action potential shape and duration, thereby regulating membrane excitability and Ca 2+ signalling;
• Mechanisms altering the physiological role of BK channels leading to either a loss-or gain-of-function have both been linked to seizure onset;
• Efficacy has been demonstrated for both channel openers and blockers in preventing seizures;
• BK channels might also be involved in epileptogenesis, however, no studies on the efficacy of BK channel modulators in preventing epileptogenesis have been performed so far;
• The molecular structure of BK channels is described and allows the possibility of several target sites for potential pharmacological modulation. each subgroup also exhibit distinct pharmacological and biophysical characteristics [1] [2] [3] [4] . In addition to their important regulatory roles, Ca 2+ -activated K + channels also have an important potential as targets for novel therapeutic drugs in health and disease [5] [6] [7] . The BK channel (also referred to as BKCa, MaxiK, Slo1, KCa 1.1 ) was the first of the Ca 2+ -activated K + channels to be identified and is one of the most widely expressed channels in mammalian cells and tissues such as neurones, skeletal, smooth and cardiac muscles, exocrine cells, and the inner sensory hair cells of the cochlea [8] [9] [10] . BK channels are also unique in being activated both in response to membrane depolarization and an increase of [Ca 2+ ] i intracellular [Ca 2+ . This sensitivity of BK channels to intracellular H + ions could be an important mechanism contributing to termination of epileptic seizure events, known to be associated with intracellular neuronal acidification 14 . BK channel functions can also be regulated by ubiquitination and palmitoylation, which seem to control the cell surface expression and activity of BK channel proteins. Indeed, myristoylation seems to allow endocytosis [15] [16] [17] . Additionally, other endogenous mediators such as arachidonic acid, NO, zinc, GMP, cGMP and cAMP-mediated phosphorylation of the channel may regulate BK channel activity 13 .
In neurones, the activation of BK channels results in an increased efflux of K + from the cell (outward current); as a consequence, the membrane potential is driven in a negative direction (decreased cell excitability) and voltage-dependent Na + and Ca 2+ channels are closed, so the probability that an AP is triggered is decreased. Therefore, these channels function as "negative feedback regulators" of membrane potential and [Ca 2+ ] i and play crucial roles in several physiological functions, such as controlling the inter-spike interval and spike frequency adaptation, neurotransmitter release, endocrine secretion, tuning hair cell tuning frequencies, as well as urinary bladder and respiratory neurone network 'tone'.
More recently, it has been recognised that BK channels can associate with a variety of G . Dysfunction of BK channels has been implicated in the onset of certain epilepsies, motor deficits, hypertension, asthma, abnormal circadian rhythms, defects in immunity and other disorders [19] [20] [21] [22] . Defective BK channels are also thought to contribute to the physiopathology of neurological disorders such as schizophrenia 23 , autism and mental retardation 24 .
Epilepsy involves alterations of normal physiological processes in the brain. An epileptic seizure is produced by synchronous and sustained firing of a population of neurones. Both excitatory and inhibitory influences may be altered, creating a predisposition towards excessive synchrony within neuronal populations 25 . About 50 million people in the world now have epilepsy, and it is estimated that 40-70 new cases per 100,000 individuals in the general population will acquire the disease every year in developed countries, with the risk being twice as high in developing countries 26 . Although approximately 70-80% of humans with new-onset epilepsy eventually enter sustained seizure remission during treatment, important, unmet needs exist in the drug treatment of epilepsy, including the development of more effective and safer AEDs 27, 28 . The aim of this review is to examine current knowledge on the molecular properties, pharmacology and genetics of BK channels with a particular attention to their possible relevance in the pathophysiology of epilepsy and the likelihood of developing new drugs that target BK channels as novel antiepileptics.
Molecular structure of BK channels
Structurally, BK channels share some similarity with the voltage and ligand-gated K + channel superfamily ( Figure 1 ). BK channel proteins are multimeric structures (homotetramers)
composed of four identical pore-forming α subunits (BKα) each comprising of seven transmembrane segments (S0-S6) and a large intracellular C-terminus region 19 . BKα can be coassembled with four different auxiliary modulatory β-subunits (β1-β4), as well as a family of leucine-rich repeat-containing subunits (LRRCs) also called γ-subunits. Each type of β-and γ-subunit displays a distinct tissue-specific expression pattern and differently affects the conductance properties, inactivation, gating kinetics and pharmacology of the assembled channel [29] [30] [31] . β2-4 subunits are neuronally expressed, whereas β1 subunits are mainly distributed in smooth muscle cells 9 . BKα is encoded by a single gene (Slo1, KCNMA1), with 27 constitutive exons and multiple alternative exons spanning. The BK gene was first discovered in Drosophila as the slowpoke mutation (dSlo) and later was identified also in mice (mSlo1) and humans (hSlo1 33, 34 . These interactions are critical for activation of the channel in response to physiological changes of membrane potential, and intracellular levels of Ca 2+ and Mg
2+
. Briefly, the voltage-sensing domain (VSD) characteristically located within the trans-membrane segments S1-S4 is able to sense membrane potential, whereas the segments S5-S6 form the pore gate domain (PGD) and within its resides, the activation gate, which controls the K + flux through the channel 32, 35, 36 . Moreover, S6 is believed to serve as the major structural determinant for the channel gate. The primary voltage sensor is located on the S4 helix, which contains many positively charged residues (basic residues) but only one of these, has been shown to participate in voltage sensing 37 . VSD and PGD, also called the membrane-spanning domains, can interact through the S4-S5 linker and S6
37
.
Furthermore, BK channels have a hydrophobic segment (S0) that leads to an extracellular NH 2 terminus and additional four intracellular hydrophobic segments (S7-S10) in the Cterminus. The first transmembrane segment, S0, is required for β-subunit modulation and can participate to modulate voltage sensitivity. The third domain is the cytosolic domain (CTD), which confers on the BK channels the ability to respond to changes in [Ca 2+ ] i and other stimuli.
The crystal structure of the BK channel in the intracellular C-terminus has defined two tandem RCK (regulator of K + conductance) domains, RCK1 and RCK2
36
. . Likewise, PGD and CTD can connect through the C-linker peptide and its length affects the activity of BK channel. Moreover, other residues located in the C-terminus allow the linking with molecules, such as heme and carbon monoxide, which modulate the gating properties of the BK channels 41 . The cytosolic region also includes phosphorylation sites for protein kinase A (PKA) and protein kinase C (PKC).
Generally, PKA phosphorylation leads to BK channel enhancement, whereas PKC phosphorylation leads to channel inhibition.
The four β-subunits (β1-4) are encoded by a specific gene KCNMB1-4 (human) or kcnmb1-4 (mouse). These BK channel subunits have two transmembrane domains (STM1 and STM2)
connected by a large loop on the extracellular side. Moreover, β-subunits show an intracellular N-terminus and C-terminus. Each β-subunit is located between two adjacent α-subunits and alters the pharmacological sensitivity of BK channels, as well as their regulation by phosphorylation, which involve multiple distinct mechanisms. For example, BKβ subunits 1, 2 and 4 seem to stabilize the BK VSD in the active conformation, whereas BKβ 2 and 3 subunits confer BK channel inactivation via an N-terminal inactivation ball, and related minor K + efflux 31, 42, 43 . In most tissues, the BKα subunit can be linked with up to three β-subunits 42 .
So far, it has not been possible to elucidate how the interdomain interactions among the three main domains VSD, CTD, and PGD are modified by β-subunits to influence channel activation 7, 9 . The ability of γ-subunits to bind and to modify BK channel kinetics and gating behaviour still remains unclear. However, it seems that all γ-subunits enhance voltagedependent activation of BK channels 30, 31 .
[ Figure 1 near here]
Expert Opinion On Therapeutic Targets . In CNS areas, such as cortex, hippocampus and cerebellum, α-subunits have also been detected in the inner mitochondrial membrane (mitoBK). Similarly to BK, mitoBK is selectively permeable to K + and is activated by both voltage and [Ca 2+ ] i . It seems that there are, at least, two type of mitoBK in the brain, but so far, their structure remains unknown 47 .
The β-and γ-modulatory subunits have a limited expression pattern in the brain. The β4-subunit is the most expressed neuronal subunit. This subunit, in a Ca 2+ concentrationdependent manner, produces mixed effects on BK channel gating. In particular, in the presence of a low local Ca 2+ concentration, the β4-subunit decreases the activation of BK channels, whereas at high Ca 2+ concentration, the BK channel activation is increased. The other subunits expressed in the brain are β2 and β3, whereas smooth muscle cells primarily express the β1 subunit 29, 48 . . The β2-subunit is able to confer N-type inactivation to BK channels, which are sensitive to block by iberiotoxin (from the red scorpion Buthus tamulus) and charybdotoxin (from the scorpion Leiurus quinquestriatus). In the CNS, these types of BK channel are mainly localized in the hippocampus; and they seem to be responsible for the early repolarization after a short burst train of APs in a train. Interestingly, the β4-subunit renders type II BK channels refractory to iberiotoxin and charybdotoxin block, but they are selectively inhibited by martentoxin, a peptide purified from the venom of the East-Asian scorpion Buthus martensi 51 . Moreover, type II BK channels are less sensitive to [Ca 2+ ] i and have slow gating kinetics.
Type I BK channels have relatively fast gating kinetics and are sensitive to scorpion venom block 35, 43, 46 . The study of the role of these channels in the CNS has been facilitated by iberiotoxin and other inhibitors, such as paxilline, lolitrem B (from the ryegrass fungus Acremonium lolii) and penitrem A (from Penicillium cyclopium) 52 . 10, 53 .
The AHP, following single or longer bursts of APs, is composed of multiple kinetic components that have been well characterized in the hippocampus 54 . In hippocampal CA1
neurones, it was possible to discern three potassium conductances; the fast component influx, is mediated by SK channels and is blocked by the bee venom toxin, apamin 55 . By contrast, the slow AHP (sAHP) evoked after a longer (~1s) burst of APs, shows a prominent activation phase (τ rise ~ 600 ms), and decays slowly, persisting for as long as several seconds.
In particular, during an AP, membrane depolarization and the increment of cytosolic Ca
2+
activate BK channels with a reduction of AP frequency. During a fAHP, the membrane potential is more negative than the normal resting potential, and returns to baseline slowly. In fact, the loss of BK current in a neurone is linked with reduction of the AHP, resulting in a higher AP frequency and enhancement of membrane excitability. This delay of the membrane potential to reach the normal resting potential after depolarization, results in increased interspike intervals and ultimately in control of neuronal excitability 53, 56, 57 . Following a fAHP, many neurones show a prolonged AHP that is generated by SK channels. This prolonged AHP also plays an important role in controlling spike frequency 57 . Targets   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58 during ischaemia or seizures, BK channels may act as an "emergency" protective system to counteract excitotoxic damage 46, 58 .
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Generally, BK channels in the hippocampal CA1 pyramidal cell layer reduce the frequency and duration of APs. However, in the past, experiments in rat CA1 pyramidal cells have remarked on the ability of BK channels to enhance early high-frequency firing. The reason for this facilitation seems to be related to the rapid spike repolarization and fAHP, which can restrict the activation of other slower potassium currents and inactivation of the fast AP Na + current 46, 53 . Interestingly, blocking the BK-mediated fAHP with paxilline resulted in an impairment of hippocampus-dependent learning during trace eyeblink conditioning in rats 59 .
BK channels have also been localized in the inner mitochondrial membrane, but their exact role in these organelles is unclear. They are, however, known to be important for Ca 2+ ion sequestration and for K + transport. The opening of mitoBK channels actually produces a loss (depolarization) of the inner mitochondrial membrane potential, which may have a protective function, fundamental for the regulation of mitochondrial metabolism 60 . Indeed, some findings indicate neuroprotective properties for mitoBK in specific brain structures 8, 61 .
Pharmacologically, mitoBK channels are unusual, in that they are blocked by iberiotoxin but not by charybdotoxin 62 . It has also been suggested that BK channels are present on the Expert Opinion On Therapeutic Targets   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58 
BK channels and epilepsy pathophysiology
Under physiological conditions, through a negative feedback mechanism, BK channels modulate both neuronal membrane potential and intracellular Ca 2+ signalling, actions that should in principle, attenuate epileptic seizure bursts. In fact, BK channels, by linking changes in intracellular Ca 2+ to a fast hyperpolarizing response, would be expected to decrease or prevent neuronal hyperexcitability that would lead to seizures. Thus, mechanisms altering the physiological role of these channels, such as gene mutations, down or upregulation of channel expression, or defects in channel trafficking and insertion into the plasma membrane could contribute to the onset of seizures, as well as other neurological diseases. In particular, studies have indicated a seizure-related down-regulation of BK channels in the hippocampus of chronically epileptic rats. Moreover, seizure-mediated BK down-regulation of BK channels principally localized at glutamatergic terminals, could also affect neuronal excitability by influencing presynaptic control of glutamate release, with a consequent facilitation of seizure events. Thus, it seems that altered BK channel expression is a plastic modification mechanism that can affect the network excitability in these epileptic animals 64, 65 .
Both gain-and loss-of-function mutation of genes encoding for the BK channel subunits have also been correlated to channelopathies leading to epilepsy disorders. Because the normal function of BK channels generally reduces neuronal excitability, loss-of-function mutations related to these channels gives rise to neuronal hyperexcitability, which can lead to seizures.
A single base pair deletion in exon 4 (delA750) of the gene encoding for the β3 regulatory 66, 67 . On the other hand, a study has also highlighted the presence of a gain-of-function gene mutation in the α-subunit (KCNMA1) on chromosome 10q22 in the pathogenesis of a human syndrome characterized by generalized epilepsy and paroxysmal dyskinesia. The mutation led to an increase in BK openchannel probability, which the authors proposed led to an increased excitability in vivo by inducing rapid repolarization of APs, thereby permitting neurones to fire at a faster rate 20 .
Likewise, a gain-of-function in a mouse knockout of the inhibitory β4-subunit has also been linked to epilepsy, most likely through a similar 'sharpening' effect on APs 68 .
In animal models of epilepsy, the loss-of-function mutation has been involved in the Deregulation of this physiologic mechanism gives rise to a release of deubiquitinated BK channels from the ER to the plasma membrane, leading to significantly increased channel activity. Mice with the CRL4A CRBN mutation in the brain or treated with a CRL4A CRBN inhibitor are very susceptible to seizure induction, which can be reduced by blocking BK Expert Opinion On Therapeutic Targets   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 60 It has been demonstrated that the BK channel β4-subunit reduces dentate gyrus excitability and protects against temporal lobe seizures, thus β4 knockout mice present temporal lobe seizures emerging from the dentate gyrus . It has been demonstrated that the presence of β1, β2, and β4-subunits of BK channels enhances the D434G mutation. It was also reported that polymorphism in the β4-subunit is associated with human epilepsy 71 .
The mitochondrial mitoBK has also been associated with various disorders including epilepsy; however, the mechanism by which functional deficits in mitoBK take part in epileptogenesis is unclear. Nevertheless, the possible role of these channels in suppressing seizures could be due both to a reduction of the production of reactive oxygen species (ROS) and to reduction of the accumulation of deleterious intra-mitochondrial Ca
2+72
. .
BK channel modulators as potential antiepileptics
The potassium channel superfamily represents a rich source of potential targets for therapeutic intervention. In view of the likely role of BK channels in the aetiology of epilepsy and other neurological disorders 24 , a major goal would be to discover selective activators, modulators and blockers of these channels, which could be useful in epilepsy therapy and perhaps also for treating many other central and peripheral vascular diseases 78 . The activity of BK channels is known to be modulated by many endogenous factors, such as acidification, phosphorylation,
, ROS, methionine oxidation, cholesterol, arachidonic acid, unsaturated free fatty acids such as the omega-3 docosahexaenoic acid and hormones (17β-estradiol and other sex and stress steroids). Therefore, drugs that affect the generation of these factors would be expected to also modify BK channel activity. In agreement with this notion, some known endogenous modulators have been used as a basis for the development of novel compounds with BK channel modulatory activity. Notably, some of these compounds regulate BK channel function in an β-subunit dependent manner 79, 80 . However, also natural and synthetic compounds may modulate BK channel activation. Among natural compounds, terpenes, phenols and flavonoids are able to stimulate BK channels 81 , but also represent an interesting group of compounds that could be used as a suitable scaffold to discover novel BK activators 52 .
[ Table 1 near here] Studies have reported the effects of the anorexogenic hormone leptin and insulin to reduce epileptiform-like activity in rats and mice hippocampal neurones. Leptin inhibits hippocampal neurones by activation of BK channels and K(ATP) channels, a process that can be important in regulating neuronal excitability. It seems that the process leading to activation of BK channels involves stimulation of phosphoinositide 3-kinase (PI 3-kinase), but not mitogenactivated protein kinase (MAPK). Exactly the opposite has been observed for insulin. Indeed, insulin inhibits neuronal excitability via a process involving MAPK-driven activation of BK and K(ATP) channels. Leptin effects were mimicked by the synthetic BK channel activator
BK channel openers/activators in epilepsy
benzimidazol-2-one), and inhibited by the BK channel inhibitors, iberiotoxin and charybdotoxin. Therefore, this novel action of these hormones could be an alternative therapeutic target in the management of epilepsy. Recently, it was argued that the neuroprotective effects of leptin in NMDA-exposed cortical neurones in vitro, were dependent on BK channel activation, supporting the potential of targeting these channels in neurodegenerative diseases 82, 83 .
The BK channel openers, isopimaric acid, chlorzoxazone (and NS1619) have been demonstrated to moderate inhibition of epileptiform activity induced by 4-aminopyridine (4-AP) in cultured rat hippocampal neurones, whereas other BK channels openers such as NS309, DCEBIO, and 1-EBIO showed potent antiepileptic anti-epileptiform effects similar to conventional antiepileptic drugs (AEDs) [82] [83] [84] . The use of NS1619 is however, limited by a relatively poor potency. In view of this poor activity, NS1619 was used as scaffold to generate the biarylthiourea NS11021, a potent compound useful to study the role of BK channels. Unfortunately, to date, there are no reports that link this compound with epilepsy. . Riluzole, a drug approved in the treatment of motoneurone disease, has been found to stimulate BK channels in rat pituitary GH3 cells 86 .
Expert Opinion On Therapeutic Targets
The efficacy of riluzole against seizures in several animal models was previously reported 87, 88 ; however, the contribution of BK channels to the anticonvulsant effects of riluzole certainly needs to be further investigated.
It was asserted that oestrogen and xenoestrogens may modulate BK channels, and, for some of these steroids, the presence of a β-subunit seems to be pivotal for their action. However, the binding site and exact mechanism of action of these compounds are unknown 89, 90 .
Hormones, such as oestrogens, play an important role in epilepsy 91, 92 . Tamoxifen, a selective oestrogen-receptor modulator, seems to bind to these channels on the extracellular side. It has been shown that tamoxifen enhances the antiseizure efficacy of some AEDs against electrically and pentylenetetrazole-induced seizures in mice. These antiepileptic effects of tamoxifen could also be the consequence of BK channel modulation 93, 94 . 96, 97 . These latterCA inhibitors, such as acetazolamide (also a sulphonamide), are known to have anticonvulsant activity, and a similar mechanism might also contribute to the anticonvulsant effects of topiramate (an O-sulphamate derivative) 98 . It has been demonstrated that acetazolamide, at concentrations higher than those required for the inhibition of CA, were able to activate BK channels in skeletal muscle.
Therefore, the antiepileptic effect of CA inhibitors could also be related the activation of these channels in neurones 99, 100 . However, CA inhibitors might also influence BK channel activity by altering brain pH. Similarly, COX-2 is known to be rapidly induced during seizures, and COX-2 inhibitors have been demonstrated to possess antiepileptic anticonvulsant effects 101, 102 . Since arachidonic acid is known to activate BK channels, the relevance of COX-2 inhibition and arachidonic acid metabolism to the anticonvulsant action of such drugs needs to be further studied and defined 103, 104 .
[ Table 2 near here]
In several animal models, it has been demonstrated that the plasmalemma BK channels are sensitive to membrane cholesterol, their activity being depressed by a rise in levels and vice versa. Considering that AEDs are known to raise total plasma cholesterol levels in patients 105, 106 , it would be of interest to determine whether BK channels play a role. The suggested anticonvulsant and antiepileptogenic effects possessed by some statins however may not be related to changes in cholesterol metabolism 79, 105, [107] [108] [109] . Long-chain omega-3 polyunsaturated fatty acids, such as docosahexaenoic acid (DHA), found in oily fish are able to activate BK channels. Moreover, DHA decreases seizures in animal models of epilepsy in addition to having neuroprotective effects 110, 111 . It has been reported that derivatives of the alkaloid eburnamine (derived from the Apocynaceae plant family), such as vinpocetine, are able to stimulate BK channels in pituitary GH3 rat cells. Vinpocetine has shown Expert Opinion On Therapeutic Targets   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58 .
BK channel blockers in epilepsy
Previous studies (described above) have identified the ability of gain-of-function mutations giving rise to seizures both in rodent models and humans. Moreover, these studies have also Likewise, the absence antiepileptic drug ethosuximide, approved for the treatment of absence seizures, in addition to its activity on Ca v3 (T-type) channels, is also able to inhibit neuronal BK channels, thus this mechanism might also contribute to its antiepileptic activity 119, 124 . Targets   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 60 . PEA is an endogenous fatty acid amide analogue of the endocannabinoid anandamide (N-arachidonylethanolamine; AEA) and it is produced on-demand within the neuronal membrane lipid bilayer; it has several proposed mechanisms of action including PPAR-α (peroxisome proliferator-activated receptor-alpha) activation 130 . Recently, it was proposed that BK channels may act as short-term intermediates for PPAR-α anti-nociceptive actions 129, 131 .
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A further link between the endocannabinoid system and epilepsy was also recently suggested by Shirazi-zand et al.
132
; it was demonstrated that the intracerebroventricular administration of CBD increases seizure threshold for PTZ-induced tonic seizures. The BK channel blocker, paxilline did not produce significant changes in seizure threshold when administrated alone.
However, when paxilline was administrated together with CBD, it was able to decrease the Expert Opinion On Therapeutic Targets   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 60 In theory, under physiological conditions, through a negative feedback mechanism, BK channels modulate both neuronal membrane potential and intracellular Ca 2+ signalling, Targets   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 60 Usually, the activation of these types of channel leads to a reduced excitability. Therefore, it would be easy to propose that epilepsy might be treated with drugs that enhance the activation of BK channels.
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Surprisingly, only few studies have addressed the effects of selective BK channel openers in epilepsy models and no proconvulsant effects have been reported to date (summarized in Table 1 ). On the other hand, the BK channel blocker paxilline showed consistent anticonvulsant effects in various animal models of epilepsy. However, the efficacy of paxilline has been observed in models where a gain-of-function was observed. Indeed, paxilline has anticonvulsant effects in the MES model where the function of these channels might not be altered. Noteworthy, paxilline does not have any effect against PTZ-induced seizures while blocking the effects of CBD in the same model. Furthermore, it cannot be excluded that the anticonvulsant effects of the available BK channel modulators might be due to other off-target mechanisms of action possessed by these drugs, such as inhibition of Ca 2+ channels 6 .
In conclusion, while BK channels are undoubtedly involved in the regulation of neuronal excitability, their role and the effects of their modulation in the potential management of epilepsy still remain widely controversial.
Expert Opinion
The K + channel superfamily represents a rich source of potential targets for therapeutic intervention. As previously mentioned, retigabine is the only selective modulator drug (acting on M-type K + ) channels currently marketed for the treatment of epilepsy. The validity of K + Expert Opinion On Therapeutic Targets   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58 98, 124, [134] [135] [136] [137] .
Despite the great number of marketed AEDs, there is still a great need for more effective, specific and safer drugs 28 . In this light, both clinical and preclinical research in this field is clearly looking for new directions to be followed in agreement with the strong need to modify the current approach which has been followed up to date Substantial data have identified mutations and alterations in the function of BK channels both in epileptic patients and epilepsy animal models; therefore, there is no doubt that they are involved in the hyperexcitation observed in the epileptic brain. Unfortunately, the physiology of this channel allows the possibility that either an impairment or increase in BK function can lead to hyperexcitability. This latter point implies a difficulty in predicting their role even if an alteration is identified. Namely, if a gain-of-function is found, this might either be the cause or a defence mechanism for seizures. To this aim, the only available option is to directly test the effects of a BK channel agonist or antagonist; obviously, this is not a feasible clinical Page 27 of 48 Expert Opinion On Therapeutic Targets   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 60 Bearing in mind this variability, the therapeutic success of drugs acting on BK channels will be highly influenced by predictors of activity in specific syndromes; furthermore, paradoxical effects might be expected in some others. This latter consideration rises from the observation that both BK channel blockers and openers possess potential anticonvulsant/antiepileptic effects. The BK channel blocker paxilline was found to be anticonvulsant in some models while blocking the anticonvulsant effects of CBD in another one. BK channels contribute to the fAHP and therefore their activation should be considered as a valid tool to decrease neuronal excitability; in other words, BK channel blockers should always be pro-convulsant or at least reduce seizure threshold. However, there are no reports for paxilline being proconvulsant. The complexity brought by modulation of BK channels is reflected by the suggestion that over-activation increases AP firing rate and therefore might contribute to seizure generation and spreading; these data support the anticonvulsant effects of paxilline and/or other BK blockers in some types of seizures where this mechanism is involved. On the other hand, the possible anticonvulsant effects of BK openers might instead drive an increase in firing rate, precipitating the generation of seizures.
The potential of this research area is likely to be enormous, but assessing the risk/benefit ratio of all drugs acting on BK channels will be a great challenge. While several drugs modulating BK channels are available, data in epilepsy models are very limited. We believe that a better activity profile should be performed in order to understand whether these channels really represent a suitable target for AED development. On the other hand, it is very interesting and represents a good resource, the observation that several hormones and drugs with anticonvulsant activity can act on BK channels among their mechanisms of action; e.g. leptin,
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All these drugs were found to be openers/activators of BK channels, further supporting the idea that an increase in the function of these channels decreases excitability and therefore might contribute to the final anticonvulsant effects observed. Therefore, very selective drugs should be studied to understand their real value and the role of BK channels in epilepsy, whereas, the contribution of BK channel modulation to the anticonvulsant effects of the abovementioned drugs might indicate their potential as add-on therapies.
Finally, a very interesting area which has not previously been covered, is the role of BK channels in epileptogenesis. BK channels were found to be altered by the epileptogenic process in animal models and it remains completely unclear whether this is an adaptive response leading to the development of spontaneous seizures, or a defence response. The available data support the idea that a loss-of-function is linked to the development of spontaneous seizures and therefore, BK channels would underlie the epileptogenic process. In this light, it is not surprising that zonisamide (a BK channel activator) has antiepileptogenic effects in the WAG/Rij rat absence epilepsy model and that in the same strain, an alteration in the function of BK channels has been described 95, 138 .
Overall, BK channels are certainly a suitable target for the development of drugs to be used in the epilepsy field as well as other neurological disorders. However, the whole area seems to hide behind a curtain and the entire portrait appears to be far from being finished.
Nevertheless, the high degree of potential modulation of these channels (natural and druginduced) might offer a new approach for their future pharmacological targeting, further than indicating that BK channels have a pivotal role in several CNS functions.
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Zonisamide
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